Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A Study to Evaluate the Safety and Pharmacokinetics of AD-123 Compared to Coadministration of AD-1231 and AD-1232
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Sequence A (RT) | Experimental | Period 1 : Reference Drug(AD-1231 and AD-1232), Period 2 : Test Drug(AD-123) |
|
| Sequence B (TR) | Experimental | Period 1 : Test Drug(AD-123), Period 2 : Reference Drug(AD-1231 and AD-1232) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| AD-123 | Drug | AD-123 Oral Tablet |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Maximum concentration of drug in plasma (Cmax) | Cmax of AD-123 | pre-dose to 72 hours |
| Area under the plasma concentration-time curve during dosing interval (AUCt) | AUCt of AD-123 | pre-dose to 72 hours |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Dasom Kim | Contact | +82-31-891-5572 | dskim@addpharma.co.kr |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| H Plus Yangji Hospita | Seoul | South Korea |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| ID | Term |
|---|---|
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| AD-1231 and AD-1232 |
| Drug |
AD-1231 Oral Tablet + AD-1232 Oral Tablet |
|